. Author manuscript; available in PMC: 2017 Apr 1.

Published in final edited form as: Am J Med Sci. 2016 Jan 29;351(4):416–419. doi: 10.1016/j.amjms.2016.01.013

Table 1.

Baseline Parameters of Prostate Cancer Patients with Metformin Versus Controls

Variable	Non- Metformin n = 149 M ± SD or %	Metformin n = 138 M ± SD or %	Cramer’s V	Cohen’s d	p-value
Still living	76.5	89.9	.177	---	.003
Age at death, years^a	72.2 ± 8.3	72.4 ± 7.3	---	.015	.964
Years with prostate cancer	5.7 ± 3.4	5.6 ± 2.9	---	.034	.774
Gleason score	6.9 ± 0.8	6.8 ± 0.7	---	.141	.233
Hemoglobin A1c, %	7.3 ± 1.5	7.5 ± 1.5	---	.110	.355
Creatinine, mg/dL	2.0 ± 1.9	1.1 ± 0.2	---	.652	<.001

n = 35, 14 for non-metformin and metformin respectively